Balyasny Reports A 5.21% Passive Position In Tandem Diabetes Care

Atlas Diversified Master Fund directly owns the shares, while Tandem plans U.S. and Canadian product additions in 2027.

Share
Balyasny Reports A 5.21% Passive Position In Tandem Diabetes Care

Balyasny Asset Management, an investment manager, reported a 5.21% passive position in Tandem Diabetes Care, which designs and sells insulin pumps and related software, in an SEC ownership disclosure filed Monday. The position comprised 3,624,727 common shares as of September 30, directly held by its investment-management client Atlas Diversified Master Fund.

Atlas Owns The Shares

Atlas has the right to collect dividends and proceeds from sales of the shares. Balyasny Asset Management may be treated as their beneficial owner because its role as investment manager gives it voting and investment authority over the fund's holding.

The reporting parties certified a passive holding: they bought and hold the stock through ordinary business activity, without seeking to change or influence Tandem's control.

The approximately 5.21% figure uses 69,578,707 outstanding common shares as of August 3, 2026, cited from Tandem's quarterly report filed August 6, 2026.

Mobi Gets A Tubeless Option

Tandem announced FDA clearance Friday for a cartridge and infusion set that let patients use Mobi without tubing. Patients with existing Mobi pumps can use the accessories without replacing their pumps.

Mobi and Tandem's t:slim X2 pumps connect with continuous glucose monitoring sensors. The company's Control-IQ+ algorithm automatically adjusts insulin dosing. Tandem also sells disposable cartridges and infusion sets, alongside its Tandem Source data platform and Sugarmate app.

San Diego, California, is where pumps are assembled for the business, which serves nearly 500,000 people across more than 25 countries.

Canada Widens Pump Use

Abbott's FreeStyle Libre 3 Plus sensor can work with the pump under the Canadian pump approvals detailed in Tandem's Thursday announcement. Expanded indications cover adults with type 2 diabetes and pregnancy among people with type 1 diabetes.

Tandem uses its own sales and support teams in the United States and Canada, with independent distributors fulfilling orders. Outside those markets it has mainly relied on distributors and began direct sales in 2026. Two distributors each generated more than 10% of worldwide sales in 2025.

Tandem plans to launch tubeless Mobi in the United States in the first half of 2027. It expects the Canadian additions in the second quarter of 2027.

Sources

More on Tandem Diabetes Care

All Tandem Diabetes Care (TNDM) coverage →